Brief: Biohaven Reports Phase 1 Degrader Data; Announces NDA Submission For Troriluzole In SCA
16/12/2024 13:34
Dec 16 (Reuters) - Biohaven Ltd BHVN.N :
* BIOHAVEN REPORTS POSITIVE PHASE 1 DEGRADER DATA, ACHIEVING
DEEP
TARGETED IGG REDUCTIONS IN THE LOWEST SUBCUTANEOUS DOSE TESTED;
ANNOUNCES NDA SUBMISSION FOR TRORILUZOLE IN SCA AND PROVIDES
OTHER KEY PROGRAM UPDATES
* BHV-1300 SAFE AND WELL TOLERATED IN PHASE 1
Source text: ID:nPn5K8VS4a
Further company coverage: BHVN.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biohaven
See all newsActing US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing